‘Breakthrough’ drugs included on Roche’s list of PhII/III studies axed in Q1 — with pivotal Mirros trial on the chopping block
If you dig into the small print on Roche’s Q1 report out Wednesday, you’ll find several high profile mid- and late-stage setbacks for its experimental …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
